Performance of cervical cancer screening and triage strategies among women living with HIV in China

被引:7
|
作者
Duan, Rufei [1 ]
Zhao, Xuelian [1 ]
Zhang, Hongyun [2 ]
Xu, Xiaoqian [1 ]
Huang, Liuye [1 ]
Wu, Aihui [3 ]
Li, Le [3 ]
Qiao, Youlin [1 ]
Zhao, Fanghui [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr,Dept Canc Epidemiol, Beijing, Peoples R China
[2] Kunming Med Univ, Dept Gynaecol & Obstet, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
[3] Third Peoples Hosp Kunming, Dept Gynaecol & Obstet, Kunming, Yunnan, Peoples R China
来源
CANCER MEDICINE | 2021年 / 10卷 / 17期
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
cervical cancer; HIV; performance; screening; triage; PREVENTION; NEOPLASIA; RISK;
D O I
10.1002/cam4.4152
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives To evaluate the clinical performance of liquid-based cytology (LBC), HPV tests and visual inspections with acetic acid or Lugol's iodine (VIA/VILI) as primary screening and triage strategies among Chinese women living with HIV (WLHIV). Methods WLHIV aged 18 years and older were recruited from HIV/AIDS treatment clinic in Yunnan, China from 2019 to 2020. Women were screened with self- and physician-sampling for HPV tests, LBC, and VIA/VILI. Women positive for any HPV or with cytological abnormalities were recalled for colposcopy examination and biopsy when necessary. Clinical performance of primary and triage strategies for detecting cervical intraepithelial neoplasia grade 2 or worse (CIN2+) was evaluated. Results For primary screening, sensitivity of physician-HPV tests was 100%, 89.5%, and 100% for hybrid capture 2 (HC2), cobas, and Sansure HPV, and specificity was 80.4%, 85.1%, and 72.0%, respectively. Self-HPV test achieved considerable performance with physician-HPV. Sensitivity and specificity were 61.1% and 96.3% for LBC (atypical squamous cells of undetermined significance or worse [ASCUS+]), 40.0% and 77.3% for VIA/VILI. For triaging HPV-positive women, LBC (ASCUS+), HPV-16/18 genotyping, and VIA/VILI-elevated specificity with sensitivity declined 30%-50% compared with HPV screening alone. Restricted HPV genotyping triage (HPV-16/18/31/33/45/52/58) demonstrated the optimal accuracy (89.5% sensitivity, 81.9% specificity), and was similar to HPV-16/18 with reflex LBC (ASCUS+). Combination antiretroviral therapies (cARTs) <2 years were associated with decreased specificity of HC2 (aOR: 1.87, 95% CI: 1.22-3.91) and Sansure HPV (2.48, 1.43-4.29). Conclusions Self-HPV with restricted genotyping triage is highly recommended for cervical cancer screening for WLHIV in China. Feasible triage to increase HPV specificity among women with short duration of cART is needed.
引用
收藏
页码:6078 / 6088
页数:11
相关论文
共 50 条
  • [21] Triage of HPV-positive women in cervical cancer screening
    Wentzensen, Nicolas
    [J]. LANCET ONCOLOGY, 2013, 14 (02): : 107 - 109
  • [22] Cervical Cancer Screening Rates Among Chinese Women - China, 2015
    Zhang, Mei
    Zhong, Yijing
    Zhao, Zhenping
    Huang, Zhengjing
    Zhang, Xiao
    Li, Chun
    Zhou, Maigeng
    Wu, Jing
    Wang, Limin
    Zheng, Xiaoying
    Wang, Linhong
    [J]. CHINA CDC WEEKLY, 2020, 2 (26): : 481 - 486
  • [23] Comparison of human papillomavirus-based cervical cancer screening strategies in Tanzania among women with and without HIV
    Kahesa, Crispin
    Thomsen, Louise T.
    Linde, Ditte S.
    Mchome, Bariki
    Katanga, Johnson
    Swai, Patricia
    Manongi, Rachel
    Kjaerem, Myassa
    Iftner, Thomas
    Waldstrom, Marianne
    Mwaiselage, Julius
    Rasch, Vibeke
    Kjaer, Susanne K.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (04) : 686 - 696
  • [24] Trends in Premature Deaths among Women Living with HIV/AIDS and Cervical Cancer
    Oduguwa, Emmanuella
    Dongarwar, Deepa
    Salihu, Hamisu M.
    [J]. SOUTHERN MEDICAL JOURNAL, 2020, 113 (12) : 651 - 658
  • [25] Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results
    Isidean, Sandra D.
    Mayrand, Marie-Helene
    Ramanakumar, Agnihotram V.
    Rodrigues, Isabel
    Ferenczy, Alex
    Ratnam, Sam
    Coutlee, Francois
    Franco, Eduardo L.
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2017, 26 (06) : 923 - 929
  • [26] Cervical cancer screening of women living with HIV infection: A must in the era of antiretroviral therapy
    Franceschi, Silvia
    Jaffe, Harold
    [J]. CLINICAL INFECTIOUS DISEASES, 2007, 45 (04) : 510 - 513
  • [27] Uptake of cervical cancer screening services by women living with HIV in Kajiado County Kenya
    Kamau, Caren
    Njoroge, Alice
    Makokha, Francis
    Ashing, Kimlin T.
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [28] Community cervical cancer screening and precancer risk in women living with HIV in Jos Nigeria
    F. A. Magaji
    M. I. Mashor
    S. A. Anzaku
    A. R. Hinjari
    N. T. Cosmas
    B. V. Kwaghe
    J. M. Ali
    Elizabeth N. Christian
    A. S. Sagay
    Ariel Chandler
    Imran Khan
    Robert L. Murphy
    Lifang Hou
    J. Musa
    [J]. BMC Public Health, 24
  • [29] Community cervical cancer screening and precancer risk in women living with HIV in Jos Nigeria
    Magaji, F. A.
    Mashor, M. I.
    Anzaku, S. A.
    Hinjari, A. R.
    Cosmas, N. T.
    Kwaghe, B. V.
    Ali, J. M.
    Christian, Elizabeth N.
    Sagay, A. S.
    Chandler, Ariel
    Khan, Imran
    Murphy, Robert L.
    Hou, Lifang
    Musa, J.
    [J]. BMC PUBLIC HEALTH, 2024, 24 (01)
  • [30] Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach
    Robbins, Hilary A.
    Strickler, Howard D.
    Massad, L. Stewart
    Pierce, Christopher B.
    Darragh, Teresa M.
    Minkoff, Howard
    Keller, Marla J.
    Fischl, Margaret
    Palefsky, Joel
    Flowers, Lisa
    Rahangdale, Lisa
    Milam, Joel
    Shrestha, Sadeep
    Colie, Christine
    D'Souza, Gypsyamber
    [J]. AIDS, 2017, 31 (07) : 1035 - 1044